Gould Robert J 4
4 · Fulcrum Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Fulcrum Therapeutics Director Robert J. Gould Sells 15,000 Shares
What Happened
- Robert J. Gould, a director of Fulcrum Therapeutics (FULC), sold 15,000 shares on February 2, 2026 in an open-market transaction. The weighted-average sale price was $10.72 per share, for total proceeds of approximately $160,857. This was a sale (not a purchase), which is often routine insider liquidity rather than an expressed positive signal.
Key Details
- Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely).
- Shares sold: 15,000; weighted-average price reported: $10.72; total value: ~$160,857.
- Price range: shares were sold in multiple trades between $10.48 and $11.10 (reporting person can provide a breakdown on request).
- Footnote: Sales were made under a Rule 10b5-1 trading plan adopted August 1, 2025.
- Shares owned after the transaction: not disclosed in the provided summary of the filing.
Context
- 10b5-1 plans allow insiders to sell shares according to a pre-established plan; such sales are generally viewed as planned liquidity and provide less direct insight into the insider’s current view of the company. No option exercises, gifts, or other derivative actions were reported.
Insider Transaction Report
Form 4
Gould Robert J
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-02-02$10.72/sh−15,000$160,857→ 454,864 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Signature
/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould|2026-02-04